Search
Coffea arabica seed, roasted
go.drugbank.com/drugs/DB15603ApprovedCoffea arabica seed, roasted allergenic extract is used in allergenic testing.
Sulfameter
go.drugbank.com/drugs/DB06821ApprovedLong acting sulfonamide used in leprosy, urinary, and respiratory tract infections.
Galidesivir
go.drugbank.com/drugs/DB11676Investigational[A191451] In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses. … Galidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus.
Clonixin
go.drugbank.com/drugs/DB09218InvestigationalClonixin is a non-steroidal anti-inflammatory drug.
Ciglitazone
go.drugbank.com/drugs/DB09201ExperimentalCiglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. It is also an anti-hyperglycemic agent in the ob/ob murine model in vivo. … Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome.
Fosfructose
go.drugbank.com/drugs/DB13863InvestigationalCategories: Compounds used in a research, industrial, or household settingGlyphosate
go.drugbank.com/drugs/DB04539ExperimentalCategories: N-substituted Glycines, Compounds used in a research, industrial, or household settingRhodamine 6G
go.drugbank.com/drugs/DB03825InvestigationalCategories: Compounds used in a research, industrial, or household settingRESP301
go.drugbank.com/drugs/DB16497InvestigationalIt was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults with rifampicin-susceptible pulmonary tuberculosis in a recruiting … RESP301 was also studied in a terminated trial (NCT05101915) for patients with mycobacterium abscesses and cystic fibrosis and in a completed trial with results (NCT04460183) for efficacy and safety in
Pemoline
go.drugbank.com/drugs/DB01230ApprovedIllicitWithdrawnIn 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.